LONDON, April 19, 2016 /PRNewswire/ --
Angle has announced results from a metastatic breast cancer research study carried out by its KOL partner University of Southern California (USC) Norris Comprehensive Cancer Center. Headline data potentially prove that circulating cancer cells (CTCs) captured using Parsortix have the same biology compared to invasive tissue biopsy and can be used to guide the treatment. While this will have to be replicated in larger-scale trials, it represents a potential third clinical application, in which Parsortix can establish a new standard of care.
Angle will now focus on implementing a clinical trial in partnership with USC and other centers. When there is more clarity about commercialization in terms of timelines and positioning, we will review our financial forecasts and the assumptions underlying our DCF-based valuation, which is unchanged at $136m or $23.0/share.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com
About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority .
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
For more information please contact:
Jonas Peciulis Edison Investment Research +44(0)20-3077-5728
Lala Gregorek Edison Investment Research +44(0)20-3681-2527
SOURCE Edison Investment Research